We will develop and deliver new drugs to patients with diseases that have unmet medical needs, with the cooperation of leading scientists in Japanese medical research. The first project we are working on is the development of therapeutics for viral infections which have no treatment.
RKP00156, which is a candidate compound for a drug created through joint research with Professor Masatoshi Hagiwara of the Graduate School of Medicine, Kyoto University, has a unique mechanism that halts the proliferation (transcription) of virus genomes in almost all DNA viruses, enabling us to treat a variety of viral disorders.
The clinical development of RKP00156 for the treatment of Cervical Intraepithelial Neoplasia (CIN), the pre-cancer state of cervical cancer which is caused by the continuous infection of human papillomavirus (HPV), will be commenced this year. The current only treatment for CIN is the extraction of uterine cervix or the entire uterus before developing into malignant tumor. Since no effective treatment drugs are available for CIN, our solution would have rescue suffering women and reduce the social and economic burden arise from the disease.
KPO1143 is another compound for the treatment of neurodegenerative disorders. In an age of shifting toward 100 year-lifespan, the development of effective treatment medicine for Alzheimer’s disease is an urgent issue. The compound targets Dyrk1a gene belonging to Trisomy 21 which causes Down’s syndrome, the genetic disorder known to lead to the early onset of Alzheimer's disease. With the cooperation of Kyoto University and Tokyo Medical and Dental University, we have found the candidate agent to significantly improve cognitive decline in animal models. In ongoing joint research with the National Institute of Radiological Sciences, verification studies are conducted using brain imaging technology developed by this institute. We aim to develop this compound and deliver it to patients as soon as possible.
We have the experience and management ability to realize the potential of academia drug discovery as medicines, and we hope to contribute to the creation of a society where people all over the world can live in health through this activity.
CEO Masafumi Kuroishi